DALLAS, Aug. 18, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Hemispherx Biopharma Inc. (AMEX:HEB) should be of particular interest to biopharmaceutical companies: Schering-Plough Corp. (NYSE:SGP), Pfizer Inc. (NYSE:PFE), Merck & Co. Inc. (NYSE:MRK) and GlaxoSmithKline plc (NYSE:GSK).
It is available at: http://www.beaconequity.com/i/HEB
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Hemispherx Biopharma Inc. (HEB) is a developer, maker and distributor of natural immune system drug therapies for the treatment of a variety of viral and immune-based disorders. The Company's new drug therapies include Ampligen, as well as Alferon N and Injection. Ampligen is currently under early clinically development for the treatment of Chronic Fatigue Syndrome (CFS). Ampligen's applications also include its use as an adjuvant for the development of therapeutic and preventative vaccines.
In the report, the analyst notes:
"In the case of HEB, however, successful monetization of its product line lies in the Company's most timely development of its drug candidate, Ampligen, an experimental therapeutic for the H5N1 virus. The PolyI: PolyC12U has been noted by the publication, Therapeutics and Clinical Risk Management, as the lead adjuvant candidate for mucosal vaccines.
"On August 10, in a conference call to discuss the Company's latest fiscal results, management said it intends to target 25 million-50 million dosages of Ampligen per year, and a minimum of 100 million dosages of Alferon LDO. These initiatives are expected to cost $10 million."
To read the entire report visit: http://www.beaconequity.com/i/HEB
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions and information free of charge exclusively to individuals who wish to receive them.